Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|19|5|927-939

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.5, 2013-02, pp. : 927-939

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erlotinib in non-small cell lung cancer: a review

By Blackhall Fiona H   Rehman Shazza   Thatcher Nicholas  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 6, 2005-06 ,pp. : 995-1002

Informa Healthcare

Access to resources Recommend Favorite

Sorafenib in non-small cell lung cancer

By Zhang Jianjun   Gold Kathryn A   Kim Edward  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 9, 2012-09 ,pp. : 1417-1426

Informa Healthcare

Access to resources Recommend Favorite

Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer

By  

Current Pharmaceutical Design, Vol. 20, Iss. 24, 2014-05 ,pp. : 3933-3943

Bentham Science Publishers

Access to resources Recommend Favorite

Reviewing the safety of erlotinib in non-small cell lung cancer

By Reck Martin   Mok Tony   Wolf Jürgen   Heigener David   Wu Yi-long  

Expert Opinion on Drug Safety, Vol. 10, Iss. 1, 2011-01 ,pp. : 147-157

Informa Healthcare

Access to resources Recommend Favorite

Erlotinib: a new therapeutic approach for non-small cell lung cancer

By Bonomi Philip  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 8, 2003-08 ,pp. : 1395-1401

Informa Healthcare

Access to resources Recommend Favorite